Allergy TherapeuticsLSE:AGY +2.17% Days Payable is 113.68 as of Dec. 2025, which is 74% above its 10-year median of 65.18. The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, Allergy Therapeutics ranks better than 73.21% on this metric.
The historical rank and industry rank for Allergy Therapeutics's Days Payable or its related term are showing as below:
LSE:AGY'
s Days Payable Range Over the Past 10 Years
Min: 42.22 Med: 65.18 Max: 145.21
Current: 145.21
During the past 13 years, Allergy Therapeutics's highest Days Payable was 145.21. The lowest was 42.22. And the median was 65.18.
LSE:AGY's Days Payable is ranked better than 73.21% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs LSE:AGY: 145.21
Allergy Therapeutics's Days Payable
declined
from Dec. 2024 (126.45) to Dec. 2025 (113.68).
It may suggest that Allergy Therapeuticsaccelerated paying its suppliers.
Allergy Therapeutics Days Payable Related Terms
Allergy Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Allergy Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:AGY vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allergy Therapeutics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Allergy Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Allergy Therapeutics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allergy Therapeutics (LSE:AGY) has a Days Payable of 113.68 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Allergy Therapeutics and its competitors. This is 74% above median its historical median of 65.18. Over the past decade, Allergy Therapeutics' Days Payable has ranged from 42.22 to 145.21. According to the industry distribution chart, Allergy Therapeutics ranks #247 out of 922 companies in the Drug Manufacturers industry, placing it in the top 26.8%.
Is Allergy Therapeutics' Days Payable too high?
Allergy Therapeutics' current Days Payable of 113.68 is 74% above median its 10-year median of 65.18. Over the past 10 years, this metric has ranged from a low of 42.22 to a high of 145.21. The Drug Manufacturers industry median Days Payable is 90.84. Allergy Therapeutics' value of 113.68 is 25.1% above this industry median. Based on the distribution chart, Allergy Therapeutics ranks #247 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Allergy Therapeutics' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #247 out of 922 companies for Days Payable. This puts Allergy Therapeutics in the upper half of its industry. The industry median Days Payable is 90.84. Allergy Therapeutics' value of 113.68 is 25.1% above this benchmark. Historically, Allergy Therapeutics' own Days Payable has ranged from 42.22 to 145.21 over the past decade. While the company's 10-year median is 65.18 vs. the industry median of 90.84, Allergy Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allergy Therapeutics's current Days Payable of 113.68 is 25.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Allergy Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current Days Payable is 113.68, which is 74% above median its own 10-year median of 65.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 120% above its estimated fair value. The current Days Payable is 113.68, which is 74% above median its 10-year median of 65.18 and 25.1% above the Drug Manufacturers industry median of 90.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current Days Payable is 113.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AGY has been successfully added to your 